Phreesia, Inc. (NYSE:PHR) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Phreesia, Inc. (NYSE:PHR) by 11.6% during the 4th quarter, Holdings Channel reports. The firm owned 12,757 shares of the company’s stock after purchasing an additional 1,324 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Phreesia were worth $295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Phreesia by 25.4% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 39,386 shares of the company’s stock valued at $912,000 after buying an additional 7,976 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in shares of Phreesia by 23.1% during the 4th quarter. Conestoga Capital Advisors LLC now owns 77,335 shares of the company’s stock valued at $1,790,000 after purchasing an additional 14,520 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Phreesia by 1,987.3% in the 4th quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock worth $34,000 after purchasing an additional 1,411 shares during the last quarter. WoodTrust Financial Corp acquired a new position in shares of Phreesia in the 4th quarter worth approximately $382,000. Finally, Trust Point Inc. bought a new stake in shares of Phreesia in the 4th quarter worth approximately $239,000. Institutional investors own 92.10% of the company’s stock.

Insider Activity at Phreesia

In other Phreesia news, COO Evan Roberts sold 25,962 shares of the company’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $23.52, for a total value of $610,626.24. Following the transaction, the chief operating officer now directly owns 728,570 shares of the company’s stock, valued at approximately $17,135,966.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, General Counsel Allison C. Hoffman sold 1,238 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $22.86, for a total transaction of $28,300.68. Following the transaction, the general counsel now owns 135,621 shares in the company, valued at approximately $3,100,296.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Evan Roberts sold 25,962 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $23.52, for a total transaction of $610,626.24. Following the completion of the sale, the chief operating officer now owns 728,570 shares of the company’s stock, valued at $17,135,966.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,947 shares of company stock valued at $1,909,216. Insiders own 5.80% of the company’s stock.

Phreesia Stock Performance

PHR stock opened at $22.32 on Monday. The firm has a 50 day simple moving average of $23.26 and a 200 day simple moving average of $21.63. Phreesia, Inc. has a 52 week low of $12.05 and a 52 week high of $34.98. The stock has a market cap of $1.26 billion, a P/E ratio of -8.86 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.78 and a current ratio of 1.78.

Phreesia (NYSE:PHR) last issued its earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The company had revenue of $95.00 million during the quarter, compared to analyst estimates of $93.52 million. During the same quarter last year, the business posted ($0.72) EPS. The company’s revenue for the quarter was up 24.0% on a year-over-year basis. Research analysts anticipate that Phreesia, Inc. will post -1.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on PHR shares. Raymond James reaffirmed an “outperform” rating and issued a $30.00 price target (up previously from $25.00) on shares of Phreesia in a report on Friday, March 15th. Truist Financial began coverage on Phreesia in a report on Monday, February 26th. They set a “buy” rating and a $35.00 target price for the company. JMP Securities increased their price target on Phreesia from $28.00 to $30.00 and gave the company a “market outperform” rating in a research report on Thursday, March 21st. DA Davidson restated a “neutral” rating and set a $32.00 price objective on shares of Phreesia in a report on Friday, March 15th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research note on Thursday, March 21st. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.62.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.